Por: RTTNews Health December 01, 2023
Pfizer Inc. () reported topline data from the Phase 2b trial investigating danuglipron in adults with obesity and without type 2 diabetes. The study met primary endpoint showing statistically significant change in body weight from baseline. No new safety signals were reported. High discontinuation rates, greater than 50%, were seen across all doses. Mikael Dolsten, Chief Scientific Officer & President, Pfizer Research and Development, said:... + full article
MarketWatch USA Business December 01, 2023
Twice-daily dosages of danuglipron demonstrated placebo-adjusted weight reductions ranging from 8% to 13% at 32 weeks and 5% to 9.5% at 26 weeks. However, “While the most common adverse events were mild and gastrointestinal in nature consistent with the mechanism, high rates... + más
Did Martha Washington really name a cat after Alexander Hamilton? | The Boston Globe
'Frustration' fuels Broncos' sideline blowup in loss | ESPN
Fox Business USA Business December 01, 2023
Fox News medical contributor Dr. Marc Siegel on Pfizer’s new oral drug and employer’s trying to restrict access to Ozempic. Pfizer announced Friday that it is discontinuing development of its danuglipron after a clinical trial showed high rates of adverse side effects... + más
Pfizer drops as obesity drug halted on safety concerns | Portland Press Herald
Pfizer Shares Drop After It Halts Development of Obesity Drug Due to Safety Concerns | Time
MarketWatch USA Politics December 01, 2023
Portland Press Herald USA World June 27, 2023
Struggling to recover from waning coronavirus vaccine demand, Pfizer is racing to catch up with Novo Nordisk and Eli Lilly in an obesity-treatment market. Bloomberg photo by Stephanie Keith Pfizer shares fell after the company halted early development of an oral drug for weight... + más
Obesity in 2035 could be just as costly as COVID in 2020 | WPTV
Half Of Global Population Will Be Overweight In 12 Years: Study | RTTNews
Time USA Science June 26, 2023
shares fell after it halted early development of an oral drug for on safety concerns, raising investor anxiety about an alternative therapy the company is still developing. The drugmaker will stop work on lotiglipron based on data from phase 1 clinical trials and lab... + más
Fox Business USA Business May 24, 2023
Fox News medical contributor Dr. Marc Siegel on Pfizer’s new oral drug and employers trying to restrict access to Ozempic. Pfizer's demonstrated promising weight loss that some experts say could work just as fast as Novo Nordisk's highly sought after Ozempic. In... + más
Chelsea Handler got on the Ozempic train without even knowing it: 'Not right for me' | Los Angeles Times
People with diabetes struggle to find Ozempic as it soars in popularity as a weight loss aid | CNBC
WPTV USA Nation March 04, 2023
The global economic impact of obesity in 2035 is expected to be comparable to that of COVID-19 in 2020, according to a new report by the World Obesity Federation. half of the world’s population will either be considered overweight or obese by 2035. Even more concerning,... + más
‘Worrying’ global obesity projections for 2035 revealed in new report | New York Post
About iurex | Privacy Policy | Disclaimer |